Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2020 2
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Fung AS, et al. Among authors: batuyong e. Cancer Med. 2020 Jul;9(13):4640-4647. doi: 10.1002/cam4.3116. Epub 2020 May 7. Cancer Med. 2020. PMID: 32378799 Free PMC article.
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi H, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A, Cheung WY, Tam VC; Hepatocellular Carcinoma - Cancer Health Outcomes Research Database (HCC - CHORD) Consortium. Alghamdi MA, et al. Among authors: batuyong e. Cancer Med. 2020 Jul;9(14):4918-4928. doi: 10.1002/cam4.3228. Epub 2020 Jun 11. Cancer Med. 2020. PMID: 32529797 Free PMC article.
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.
Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Samawi HH, et al. Among authors: batuyong e. Cancer Med. 2018 Jul;7(7):2816-2825. doi: 10.1002/cam4.1493. Epub 2018 May 15. Cancer Med. 2018. PMID: 29766659 Free PMC article.
Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study.
Armstrong D, Raissouni S, Price Hiller J, Mercer J, Powell E, MacLean A, Jiang M, Doll C, Goodwin R, Batuyong E, Zhou K, Monzon JG, Tang PA, Heng DY, Cheung WY, Vickers MM. Armstrong D, et al. Among authors: batuyong e. Clin Colorectal Cancer. 2015 Dec;14(4):291-5. doi: 10.1016/j.clcc.2015.06.001. Epub 2015 Jun 18. Clin Colorectal Cancer. 2015. PMID: 26433487